News

AL Sydbank A/S Announces Data Centre Choice and Profit Shift

AL Sydbank A/S Announces Data Centre Choice and Profit Shift

AL Sydbank A/S Unveils New Data Centre Selection

Today marks a significant milestone for AL Sydbank A/S as it opens the doors to what it describes as the bank of the future. The Board of Directors has made a strategic decision regarding their IT solutions, opting for Bankdata as the future provider. This selection follows a comprehensive assessment considering functionality, financial implications, and collaborative advantages. The move signifies that AL Sydbank A/S will be transitioning away from its previous IT solutions partner, BEC.

Why Bankdata is the Right Choice

The decision to partner with Bankdata stemmed from various crucial factors. First, Bankdata offers the most effective solutions tailored to meet the intricate needs of corporate customers. This focus is essential for AL Sydbank A/S’s ambition to maintain its standing as Denmark’s preferred Corporate Bank moving forward.

Moreover, Bankdata's seamless integration with the bank’s Internal Ratings-Based (IRB) models highlighted its capabilities, paving the way for an efficient approach to obtain necessary approvals for the exposures associated with Arbejdernes Landsbank and Vestjysk Bank.

Aligning IT Development Goals

Another aspect of the decision was Bankdata’s strong commitment to cooperative IT development, underpinned by a solid shareholders' agreement. This ensures a unified approach to IT projects, enhancing resource sharing and efficiency.

Expansion into International Markets

Furthermore, the chosen IT data centre is set to bolster activities beyond Denmark’s borders, specifically aiding efforts in Germany. This alignment marks a significant step towards AL Sydbank A/S positioning itself as a favored banking partner for associations all over Denmark.

Cost Synergies and Operational Efficiency

With the decision to consolidate IT solutions at Bankdata, AL Sydbank A/S is poised to initiate steps toward realizing annual cost synergies of DKK 1,200 million. This strategic move unlocks the potential for developing a cohesive IT platform, which is fundamental in streamlining operations among the previously separate entities of the bank. Until the completion of this transition, operational efficiencies remain limited.

New Profit Forecast for 2025

In light of these changes, AL Sydbank A/S has revised its profit forecast for the upcoming year. Initially, projections indicated an after-tax profit ranging from DKK 2,400-2,600 million. However, following an expedited exit from BEC—which will necessitate an exit fee payable sooner than anticipated—the new expected profit range is DKK 1,700-1,900 million.

Moreover, merger and integration costs, previously estimated between DKK 1.5-2.5 billion, are now anticipated to fall within a tighter range of DKK 1.4-1.9 billion. This adjustment reflects a focus on maintaining financial prudence as the bank navigates its new strategic direction.

Get in Touch for Further Information

For media inquiries, please contact Louise Degn at +45 20 28 8118 or via email at louise.degn@sydbank.dk. For investor-related questions, reach out to Jørn Adam Møller at +45 61 63 55 30 or send an email to jam@sydbank.dk.

As AL Sydbank A/S embarks on this transformative journey, the future looks promising with strategic alignments and a focus on enhancing operational efficacy.

Frequently Asked Questions

What is the new IT solutions provider for AL Sydbank A/S?

AL Sydbank A/S has chosen Bankdata as its new IT solutions provider.

Why did AL Sydbank A/S switch from BEC?

The decision was based on a detailed assessment of functionality, finances, and collaboration benefits for the merged bank.

What immediate benefits does this change present?

It enables an annual cost synergy of DKK 1,200 million and allows the development of a unified IT platform.

How has the profit forecast changed for 2025?

The profit forecast has been adjusted to a range of DKK 1,700-1,900 million, down from the previous estimate of DKK 2,400-2,600 million.

What are the new expectations for merger and integration costs?

Merger and integration costs are now projected to be between DKK 1.4-1.9 billion, lower than earlier estimations.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 171

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
CapCut's AI Tools Reshape Video Content Creation

Updated Category News Views 185

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 176

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 201

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 221

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 98

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 79

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 159

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 207

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Opportunities in Oversold Tech Stocks Today

Updated Category News Views 121

Market Dynamics and Oversold Stocks Recently, we witnessed a notable sell-off in the stock market, which was fueled by rising concerns surrounding the AI industry. As a result, many stocks experienced a significant pullback. Interestingly, this downturn did not discriminate and impacted various equities, including those unrelated to the AI sector. It's essential to...

Continue Reading
Innovative Device Revolutionizes Leg Recovery Process

Updated Category News Views 109

A Breakthrough in Leg Recovery: The LEG LIFTER Recovering from an injury or surgery can be a challenging process, especially when it comes to managing mobility. An inventive entrepreneur has come up with a unique solution to assist those dealing with leg injuries. The designer, based in Marietta, has developed the LEG LIFTER, a tool aimed at facilitating the lifting and...

Continue Reading
Vizsla Silver's New Strategic Acquisition Enhances Panuco Project

Updated Category News Views 78

Vizsla Silver Expands its Footprint with Key Acquisition In an exciting development, Vizsla Silver Corp. (NYSE: VZLA) (TSX: VZLA) has entered into an agreement to acquire significant claims that will bolster its already promising Panuco project. Ten new claims totaling 2,378 hectares have been purchased from Minera Fresnillo S.A. de C.V., a Fresnillo plc subsidiary. This...

Continue Reading
C3.ai Investors Seek Justice Amid Recent Stock Concerns

Updated Category News Views 91

Understanding the Situation for C3.ai Investors C3.ai, Inc. (NYSE: AI) has recently made headlines, not for positive advancements, but due to significant concerns regarding its stock performance and allegations of misleading statements. Shareholders who purchased shares during a specific class period might have encountered substantial losses, prompting the need for...

Continue Reading
Class Action Alert for Investors of Regeneron Pharmaceuticals

Updated Category News Views 139

Investors of Regeneron Pharmaceuticals Urged to Act In the bustling world of biotechnology, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has captured significant attention. Recently, the exceptionally reputable Rosen Law Firm announced a class action lawsuit, bringing notice to shareholders who have purchased securities from November 2, 2023, to October 30, 2024. This...

Continue Reading